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The mammalian Ptdlns 3-kinase is shown to be inhibited by low nanomolar concentrations of demethoxyviridin, an antifungal agent structurally 
related to wortmannin. The inhibitory potency of both compounds could be observed in purified Ptdlns 3-kinase whether or not the regulatory subunit 
@85x) was present, suggesting that the inhibitors bind to the catalytic subunit fpl 10) of the Ptdlns 3kinase. These ~hibitors also show similar potency 
against he intrinsic p85-phosphorylating activity of the pl IO-kinase. However, the structurally related Ptdlns 3-kinase from Succharomyces cerevisae 
(Vps34p) is not inhibited by either compound. Both inhibitors target the mammalian Ptdlns 3-kinase in vitro and in vivo, implying that these 
compounds should be useful in suppressing Ptdlns 3-kinase in rna~ali~ systems. The ~~bitors did not affect the m~alian Ptdlns 4-kinase, 
but they are able to inhibit a membrane-associated Ptdlns 4-kinase from Schizosacchromyces pombe. 
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1. Introductii.ul 
The phosphatidylinositol 3kinase (Ptdlns 3-kinase) 
seems to play an important role in growth factor medi- 
ated cell transformation and mitogenesis (reviewed in 
[l-6]. The enzyme exists as a heterodimer, which con- 
tains a regulatory subunit (p8.5) and a catalytic subunit 
(pll0). The regulatory subunit (p85) is responsible for 
the association of the complex with other signal 
transduction elements a process mediated by either the 
intrinsic SH2 or SH3 domains [7-lo]. The catalytic sub- 
unit (pll0) shows homology to the VPS34 gene product 
(Vps34p) from Saccharomyces cerevisae, which is in- 
volved in protein sorting [11,12]. The Vps34p has been 
shown recently to be a Ptdlns 3-kinase [13]. 
Recent evidence has shown that wortmannin can in- 
hibit the mammalian Ptdlns 3-kinase [14,15], This anti- 
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fungal compound f16] has diverse effects in mammalian 
cells [17,18] and has been employed as a potent inhibitor 
of neutrophil activation 1191, where it blocks phospholi~ 
ase C and phospholipase D activation. Studies from this 
laboratory have shown that wortmannin does not signif- 
icantly affect partially purified mammalian phospholip- 
ase D [20] consistent with the notion that wortmannin 
targets some upstream signalling component [191. In line 
with the effect of wortmannin on the Ptdlns 3-kinase, it 
has been reported to affect Ptdlns metabolism but not at 
the level of the Ptdlns 4-kinase, Ptdlns 4-phosphate 5- 
kinase nor diacylgly~rol kinase [Zl]. Like wor~a~in 
the structurally related but distinct compound 
demethoxyviridin (DMV) has potent effects on neutro- 
phi1 activation that resemble those induced by wortman- 
nin [19]. While DMV has some inhibitory effects upon 
partially purified phospholipase D, these are seen in the 
mM range and are not consistent with the efficacy of the 
compound in vivo [ZO]. 
If Ptdlns 3-kinase is indeed the physiological target of 
wortmannin, DMV may well act at the same target en- 
zyme. In this paper we compare the ability of wortman- 
nin and DMV to inhibit complexed and free catalytic 
forms of the Ptdlns 3kinase as well as the related Vps34p 
from S. cerevisae. The data show that the mammalian 
enzyme is indeed a target for DMV as it is for wortman- 
nin. 
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2. Materials and methods 
2.1. Material and cells 
Maintenance, culture, transfo~a~ion of yeast ~S~hi~osa~chromyces 
pombe) and the construction of the expression plasmids were as de- 
scribed [22,23]. Insect cells (Sl9) and viruses were maintained as de- 
scribed earlier [lo]. Wortmannin and all lipids were obtained from 
Sigma, [Y-~~P]ATP was from Amersham. Wortmannin was also gener- 
ously provided by Dr. R. Movva, Sandoz, Base], Switzerland. 
Demethox~iri~n (DMV) was a kind gift of Dr. J. Hanson, Sussex 
University, Brighton, UK. 
2.2. Ptdims 3-kinase assay 
The lipid (Ptdlns) was dried in a nitrogen stream or under vacuum 
and then son&ted in water on ice for 10-20 s at optimum power using 
2.0 ml of water/mg lipid. The reaction mix contained 10 ,ul of enzyme 
preparation, 5 ~1 of lipid-solution, 5 .ul of 15 mM MgCl,, 20 mM 
EGTA-Na, (pH 7.4), 15 pl of water. The assay was start&l by adding 
5 ul of 10 mM ATP (nH 7.4). containina lr-32PlATP (2-5 C&m01 
ATP). For the determi;ation ofthe compegng effekts of ATP or Ptdlns 
on the inhibitory activity the assay was started by adding the enzyme 
preparation. The enzyme used was in buffer A (50 mM /J-glycerol- 
phosphate, 20 mM NaF, 10 mM benzamidine, 2 mM EDTA, 1 mM 
dithiothreitol, pH 7.4) contain~g 160 mM to 320 mM NaCl which was 
then diluted 4-fold in the assay mix. The inhibitors were added at the 
indicated concentrations. The incubation was stopped by adding 0.1 ml 
1 N HCI to the assay (40 PI), followed by 0.4 ml CHClJMeOH (2:l). 
The lower phase was removed, washed twice using each time 0.2 ml 
1 N HC~MeOH (1: 1). The phosphorylated lipids were either separated 
by thin layer chromato~aphy and the corresponding lipid-spots 
scraped out and counted or the organic phase was counted directly. 
2.3. Par~catio~ of Ptdlns 3-kinase from Sfs-cells 
The Ptdlns 3-kinase was purified by a procedure to be described 
elsewhere (R. Woscholski et al., manuscript in preparation). Briefly, the 
baculovirus expressed complex of p85a and ~110 or the pllO-subunit 
alone [ 1 l] were chromatographed on Q-Sepharose, S-Sepharose, Hepa- 
rin-Sepharose, Sephacryl S-300 and finally Hep~n-Sepharose. The 
complex (p8SalpllO) was about 90% pure, the catalytic subunit (pIlO) 
was about 30% pure as judged by sodium dodecylsulfate-poly- 
acrylamide lectrophoresis and protein staining (data not shown). The 
immobilized mammalian Ptdlns 3-kinase complex was generated by 
binding purifted complex on beads, crosslinked to.the phospho-peptide 
DY(P)~MLG, as described before [7,9]. 
2.4. Preparation of the particulate fraction from yeast expressing tke 
~rnali~ Ptdfns 3-kinase or the VPS3QPtdlns 3-kinase 
The catalytic subunit @llO) of the rn~ali~ Ptdlns 3-kinase or the 
VPS3CPtdlns 3-kinase were expressed in S. pombe [22]. Yeast particu- 
late fractions containing either ~110 or Vps34p [22] were employed for 
testing the inhibitors using the assay described above. The extracted 
lipids were separated using a borate system [24]. The Ptdlns-3-phos- 
phate spots were ident~ed by comi~ation with a [~‘P]Ptdlns-3-phos- 
phate standard. 
2.5. Protein kinase assay 
Purified Ptdlns 3-kinase was incubated for 30 min at 37“C in the 
presence of 10 mM MnCl, and 2.5 yM ATP (2 Ci&mol ATP). The 
reaction was stopped with Laemmli sample buffer and separated by 
sodium dodecylsulfate gel electrophoresis and Coomassie blue stained 
[25]. The incorporated [32P]phosphate was visualised by autoradiogra- 
phy, cut out and counted. 
For the ~mmobilised Ptdlns 3-kinase, the enzyme (lo-fold higher 
amounts than above) was treated with or without the inhibitor as 
indicated (25 or 750 nM) for 20 min at 37°C (see above). The matrix 
(30~1) was then washed two times with 1 ml buffer and then incubated 
in the presence of 10 mM MnCl, and 2.5 PM ATP (2 Ci/&mol Ap) 
for 30 min. The i~obili~d Ptdlns 3-kinase was then eluted using 0.1 
ml Laemmli buffer at 50°C (1 h), separated by sodium dodecylsulfate 
gel electrophoresis and Coomassie blue stained. 
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Fig. 1. itemization of the inhibitor potency of DMV and wortman- 
nin. Purified mammalian Ptdlns 3-kinase, either as a complex of ~110 
and p85a (Fig. IA) or as the free catalytic subunit ~110 only (Fig. 1B) 
were incubated with wortmannin (open circles) or DMV (closed circles) 
at the stated concentrations and immediately subjected to a Ptdlns 
3-kinase assay. The Ptdlns 3-kinase activity is given as the percentage 
of the uninhibited kinase activity (100%). 
3. Results and grunion 
3. I. The effect of demethoxyviridin and wortmannin on 
~~r~~ed Ptdlns 3-kinase 
Ma~alian ~8% and pllO-subunits of the Ptdlns 
3-kinase were expressed in insect cells using the bacu- 
lovirus system [lO,l 11. The Ptdlns 3-kinase (the free cat- 
alytic subunit ~110 and the complex p85c1/pllO) from 
this source were purified, and then employed to optimize 
the assay conditions (R. Woscholski et al., manuscript 
in preparation). Using this optimized assay DMV and 
wortmannin were investigated for their ability to inhibit 
the Ptdlns 3-kinase activity. As shown in Fig. lA, both 
compounds were able to inhibit heterodimeric Ptdlns 
3-kinase activity at nanomolar concentrations. These in- 
hibitors seem to be approximately equipotent; the IC-50 
values for DMV and wortmannin were determined using 
a double-reciprocal plot and were 3.4 nM and 7.1 nM, 
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pared to the complex. However, both compounds inhibit 
the Ptdlns 3-kinase regardless of the presence of the reg- 
ulatory subunit (p85a), suggesting that both inhibitors 
bind to the catalytic subunit (~110) of the Ptdlns 3-k& 
nase. 
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Fig. 2. Effect of the lipid kinase inhibitors on the intrinsic protein kinase 
activity of the mammalian Ptdlns 3-kinase. Purified Ptdlns 3-kinase 
activity was assayed in the presence of DMV (closed circles) or wort- 
mannin (open circles) using the indicated concentrations. The 
phospho~lated proteins were separated by sodium dodecylsulfate gel 
electrophoresis and then subjected to autoradio~aphy (Fig. 2A). The 
co~espon~ng p85a-bands were cut out and counted (Fig. 2B). The 
Ptdlns 3-kinase activity is given as the percentage of the uninhibited 
kinase activity (100%). 
respectively, which is in agreement with recently reported 
data using wortmannin and anti-p85cr. irnmunoprecipi- 
tates [ 14,151. Our data confirm that wortmannin is a 
potent inhibitor of the ma~alian Ptdlns 3-kinase. Fur- 
thermore, the structurally related compound DMV is as 
potent as wortmannin, suggesting that both compounds 
share structural elements important for the binding and 
inhibition of the mammalian Ptdlns 3-kinase. 
In order to investigate which subunit is targeted by the 
inhibitor, we tested the Ptdlns 3-kinase activity of the free 
catalytic subunit ~110 in the presence or absence of these 
inhibitors. As shown in Fig. lB, both inhibitors were 
able to target the free catalytic subunit (‘pll0). In con- 
trast to the data obtained for the heterodimeric Ptdlns 
3-kinase complex (see Fig. lA), the inhibitors seem to be 
different with respect to their inhibitory potency; the 
IC-50 values were calculated as 0.13 nM for DMV and 
6.2 nM for wortmannin based upon reciprocal plots. 
Thus DMV specifically displays a greater potency than 
wo~m~nin for the free catalytic subunit when com- 
Recently it has been shown that the mammalian Ptdlns 
3-kinase is associated with a protein kinase, which can 
phospho~late the regulatory subunit of the enzyme 
[26,27]. The protein kinase activity seems to be intrinsic 
to the ~110 subunit suggesting that the catalytic subunit 
is able to phosphorylate both the p85-subunit and the 
Ptdlns-lipids acting as a dual specificity kinase [26]. We 
therefore investigated the effect of the inhibitors on the 
intrinsic protein kinase activity by using purified Ptdlns 
3-kinase (pl~/p85~), which was incubated with the indi- 
cated ~on~ntrations of inhibitors (Fig. 2). Both com- 
pounds blocked the manganese-dependent protein ki- 
nase activity at concentrations higher than 30 nM. The 
estimated IC-50 values for DMV and wortmannin were 
determined using a double-reciprocal plot (not shown) as 
6.5 nM and 17.1 nM, respectively. Thus, the lipid and 
protein kinase activities of the Ptdlns 3-kinase possess a 
similar sensiti~ty with respect to the tested inhibitors. 
These data support the concept that a common catalytic 
site is involved in both lipid and protein kinase activity 
1271. 
3.2. Characterisation of the inhibitory activity 
Since it has been shown that wortmannin could bind 
in an irreversible fashion to the myosin light chain kinase 
(MLCK) and more recently the Ptdlns 3-kinase [29] 
thereby inhibiting these kinase activities, we investigated 
if DMV behaves in a similar fashion. Immobilized mam- 
malian Ptdlns 3-kinase, was incubated with 25 nM inhib- 
itor for 20 min at 37°C. The immobilised Ptdlns 3-kinase 
was removed and extensively washed (see section 2) and 
subjected to a lipid and protein kinase assay. The lipid 
and protein kinase activities were inhibited regardless of 
Table 1 
Characterisation of the inhibitory activity 
Ptdlns MM) ATP (uM) Ptdlns 3-kinase activity (%) 
DMV Wortmannin 
25 125 22.5 58.3 
250 125 14.3 39.1 
25 1250 45.2 70.0 
250 1250 34.5 61.5 
The purified Ptdlns 3-kinase (pl lO/p85a) were assayed in the presence 
of the indicated concentrations of ATP, Ptdlns and 75 nM Inhibitor. 
The lower concentrations of the substrates used were choosen to be 
approximately equivalent o the corresponding X, values (R. Wos- 
cholski et al., manuscript in preparation). The assay was started by 
adding the enzyme, allowing equal opportunity for the inhibitor and the 
competing substrates to bind. The determined lipid kinase activity is 
given as a percentage of the un~hibit~ lipid kinase activity (100%) 
under similar substrate conditions. 
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the washing procedure employed, suggesting that DMV 
could not be washed away (data not shown). We there- 
fore conclude that a very slow dissociation or an irrevers- 
ible covalent binding of the inhibitors is responsible for 
this observation, which is in agreement with earlier re- 
ported data for wortmannin using MLCK [28] or Ptdlns 
3-kinase [29]. 
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80 
In order to test the nature of the inhibition, we deter- 
mined whether the inhibition by DMV or wortmannin 
could be protected with either the lipid substrate Ptdlns 
or with ATP. As shown in Table 1, the inhibition seems 
to be unaffected by the Ptdlns-concentrations used. In- 
creasing the ATP-concentration lo-fold slightly weak- 
ened the inhibitory activity of DMV. This effect was even 
less obvious when wortmannin was used. A slight effect 
of ATP on MLCK-inhibition, using wortmannin only, 
has been reported [28]. Since ATP and Ptdlns did not 
have a profound effect on the Ptdlns 3-kinase-inhibition 
and these inhibitors bind in an irreversible fashion, we 
conclude that neither inhibitor is competitive with re- 
spect to Ptdlns or ATP. 
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Wortmannin and DMV both have been shown to be 
unstable in aqueous solutions with respect o their anti- 
fungicidal action [18,30]. We therefore investigated the 
stability of both compounds in aqueous solutions with 
respect to their inhibitory potency for Ptdlns 3-kinase. 
Aqueous solutions of DMV or wortmannin (30 FM and 
25 PM, respectively) were stored at either 37°C or on ice 
in the presence or absence of 20 mM Tris-HCl (pH 7.4). 
As shown in Table 2, both inhibitors were subject to 
destruction at neutral pH, whereas the unbuffered aque- 
ous solutions of wortmannin and DMV (pH 5.5-6.0) 
were much more stable. However, the data indicate that 
wortmannin is more stable to destruction than DMV, 
since wortmannin, in contrast to DMV, is not destroyed 
when stored at 4°C at pH 7.4. 
Fig. 3. Effect of the inhibitors on Vps34pPtdlns 3-kinase. Yeast (S. 
pombe) particulate fractions containing the Vps34p (S. cerevisae) were 
incubated with the indicated concentrations of DMV and then immedi- 
ately subjected to a Ptdlns 3-kinase assay. The extracted lipids were then 
separated using the borate system. Ptdlns-3-phosphate-spots and 
Ptdlns-4-phosphate-spots were visualised by autoradiography, scraped 
out and counted. The Ptdlns 3-kinase activity of the Vps34p (closed 
circles) and the endogenous Ptdlns 4-kinase activity (S. pombe) of the 
yeast membrane (open circles) are expressed as a percentage of the lipid 
kinase activity observed in the absence of DMV 
Wortmannin has been shown to be subject to a hydro- 
lytic opening of the furan ring which destroys its inhib- 
itory potency when it is tested on the phagocytosis- in- 
duced respiratory burst in neutrophils [18]. Since the 
DMV structure shares essential carbonyl groups and the 
furan ring with wortmannin [ 181, it is tempting to suggest 
that indeed DMV and wortmannin rely on this structural 
element for their action as inhibitors of the respiratory 
burst response [18], MLCK [28] and the mammalian 
Ptdlns 3-kinase [15]. Our data indicate that DMV, the 
more potent inhibitor (see Fig. l), is also the one more 
vulnerable to nucleophilic destruction in water. An ex- 
planation for this difference might be that DMV is miss- 
ing an oxygen in the neighbourhood of the important 
C-3 carbonyl group [18], which could therefore result in 
a strengthening of the nucleophilic character of the car- 
bony1 group facilitating the nucleophilic addition at C-20 
in the furan ring. Thus, DMV should be more reactive 
as an alkylating agent [18], resulting in both increased 
sensitivity to hydrolytic destruction and to increased po- 
tency in inhibition of the mammalian Ptdlns 3-kinase. 
Table 2 
Stability of the inhibitors in 20 mM Tris-HCl (pH 7.4) 
Inhibitor Temperature (” C) Ptdlns 3-kinase activity (%) 
DMV 0 49.9 
DMV 37 84.2 
Wortmannin 0 0.6 
Wortmannin 37 89.2 
The inhibitors (30 PM) were stored at the indicated temperature for 3 
h in the presence of 20 mM Tris-HCl (pH 7.4). The inhibitors (750 nM) 
were then introduced into a Ptdlns 3-kinase assay. The determined 
activity is given as a percentage of the uninhibited lipid kinase activity 
(100%). Storage in water alone (pH 5.5-6.0) had no effect on the 
stability of the inhibitors (data not shown). 
3.3. The inhibitors have no affect on the Vps34p-lipid 
kinase 
It has been shown recently that the product of the 
VPS34 gene from S. cerevisae isa Ptdlns 3-kinase, closely 
related in sequence over the C-terminal half of the pro- 
tein to the mammalian catalytic subunit (~110) of the 
Ptdlns 3-kinase [13,221. We therefore compared the effect 
of these inhibitors on this yeast enzyme in parallel to the 
mammalian Ptdlns 3-kinase using a yeast expression sys- 
tem [22]. 
As shown in Fig. 3, the Vps34p-Ptdlns 3-kinase was 
not subject to inhibition by DMV using concentrations 
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Fig. 4, Effects of DMV and wortmannin on the growth of the yeast S. 
po&e expressing pl10. Cells containing vector (open circles) or inte- 
grated pIlO (closed circles) were precultured for 24 h in the presence 
of the indicated concentrations of DMV {Fig. 4A) or wortmannin (Fig. 
4B) without thiamine (in order to obtain pIlO expression), and then 
shifted to fresh medium containing DMV or wortmannin at an absorb- 
ance at 600 nm of 0.05. Cell growth was determined by measuring the 
absorbance at 600 nm after a further 24 h cultivation. 
up to 400 nM. Since the Vps34p-Ptdlns 3-kinase was 
located in the particulate fraction, we tested the mam- 
malian pIlO expressed in yeast as a control [22], reveal- 
ing an almost complete inhibition of the mammalian 
Ptdlns 3-kinase activity at about 400 nM DMV, the shift 
in potency being due to the crude nature of the prepara- 
tion. When added to crude yeast extracts, purified p85al 
pl lo-kinase displayed less sensitivity to DMV (data not 
shown). Wortmannin did inhibit the pl lo-Ptdlns 3-ki- 
nase with a weaker potency than DMV, but did not 
si~i~cantly inhibit the Vps34p-Ptdlns 3-kinase activity 
(data not shown). The results suggest hat these inhib- 
itors were preferentially targeting the catalytic subunit of 
the ma~alian Ptdlns 3-kinase, whereas the related 
Vps34p-Ptdlns 3-kinase was unaffected under these con- 
ditions. 
As shown in Fig. 3, DMV (100 nM) inhibits the en- 
dogenous Ptdlns 4-kinase from yeast. Further investiga- 
tion using wild type particulate fractions from S. ~0~~~ 
revealed that an endogenous Ptdlns 4-kinase is subject to 
inhibition by DMV at about 400 nM, whereas wortman- 
nin (at 300 nM) only slightly affected this endogenous 
Ptdlns 4-kinase from yeast (data not shown). To investi- 
gate if the inhibitors would target the mammalian Ptdlns 
4-kinase, we used a particulate fraction from rat brain 
[ZO] in this assay system. In contrast to the yeast lipid 
kinase the mammahan Ptdlns 4-kinase was not affected 
by the inhibitors (data not shown). 
3.4. The Ptdhs 3-k&se is inhibited by 
~ort~an~~~ in vivu 
DMV and 
The results described above show that DMV and 
wortmannin are both able to inhibit the Ptdlns 3-kinase 
P110 catalytic activity in vitro. In order to establish if 
these compounds could inhibit the mammalian Ptdlns 
3-kinase in vivo, a yeast expression system was used to 
characterise the effect of these inhibitors on cell growth. 
In this system the introduction of the mammalian cata- 
lytic subunit of the Ptdlns 3-kinase (pl 10) results in a 
phenotype with a strongly reduced growth rate, as com- 
pared to that of the wild type S. pombe [22]. Both com- 
pounds were therefore employed to investigate whether 
they could suppress the growth in~bition evoked by the 
pl lo-expression. 
Both inhibitors, DMV and wortmannin were able to 
overcome the pl lo-induced growth inhibition at low mi- 
cromolar concentrations (Fig. 4). These results indicate 
that the inhibitors can rescue the yeast cells. However, 
in this dose range the inhibitors caused a growth inhibi- 
tion when employed against the wild type yeast cells. 
Since the in vitro data (see Fig. 3) suggest hat the DMV 
can inhibit a Ptdlns 4-kinase from yeast and Ptdlns-4 
phosphate has been shown to be indispensible in the 
yeast S. cerevisae [31], it can be concluded that the com- 
pounds may affect either this endogenous Ptdlns 4&i- 
nase, a yeast-homologue of ~110 and/or a yeast MLCK 
homologue, which is also subject to inhibition by wort- 
mannin [ZS]; a block in function of any one of these may 
be growth inhibitory. 
The data presented emonstrate that like wortmannin 
[15], demethoxyvi~din is a potent inhibitor of the mam- 
malian Ptdlns 3-kinase, in vivo and in vitro. It is also 
shown that the Ptdlns 3-kinase p85a-phosphorylating 
activity shows a similar sensitivity to these inhibitors. 
The efficacy of DMV is slightly greater than that of 
wortmannin, although its stability is significantly less. As 
alluded to above these two parameters may be related. 
Significantly, both inhibitors display similar pharmaco- 
logical properties when applied to human neutrophils 
[ 191 in a dose range similar to the observed inhibition of 
the stimulus-induced production of Ptdlns-3,4,5-t+ 
phosphate [1 S]. However, as with all inhibitors, consider- 
ations of specificity must be made. A particulate Ptdlns 
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4-kinase from S. pombe can also be in~bited by both 
inhibitors, although interestingly a particulate mammal- 
ian Ptdlns 4-kinase was unaffected. It seems that the 
compounds target the Ptdlns 3-kinase in mammalian 
cells, whereas in yeast cells a Ptdlns 4-kinase rather than 
Ptdlns 3-kinase related to Vps34p is affected. These in- 
hibitory effects on the yeast lipid kinase might contribute 
to an understanding of the fungistatic properties of these 
compounds [16,29]. In conclusion, DMV like wortman- 
nin inhibits the Ptdlns 3-kinase in the low nanomolar 
range and this effect may well underlie its ability to inter- 
fere in mammalian cell signalling. Notwithstanding the 
issue of specificity, there is no doubt that these inhibitors 
will greatly facilitate elucidation of the Ptdlns 3-kinase 
pathway. 
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